Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease

Blood

Volumn 93, Issue 6, 1999, Pages 1790-1797

  Atweh, George F ^a   Sutton, Millicent ^b   Nassif, Imad ^b   Boosalis, Vassiliki ^b   Dover, George J ^b   Wallenstein, Sylvan ^b   Wright, Elizabeth ^b   McMahon, Lillian ^b   Stamatoyannopoulos, George ^b   Faller, Douglas V ^b   Perrine, Susan P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUTYRIC ACID; FATTY ACID DERIVATIVE; HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; ERYTHROCYTE COUNT; ERYTHROID CELL; FEMALE; HEMOGLOBIN DETERMINATION; HEMOGLOBIN SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SURVIVAL TIME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BLOOD UREA NITROGEN; BUTYRATES; CELL DIVISION; ERYTHROCYTE COUNT; ERYTHROID PROGENITOR CELLS; FEMALE; FETAL HEMOGLOBIN; HEMOGLOBINS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; RETICULOCYTE COUNT; TREATMENT OUTCOME;

EID: 0033559320     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Conley CL: Sickle cell anemia - The first molecular disease, in Wintrobe MM (ed): Blood, Pure and Eloquent: A Story of Discovery, of People, and of Ideas. New York, NY, McGraw-Hill, 1980, p 319
2. Bunn HF: Pathogenesis and treatment of sickle cell disease. N Engl J Med 337:762, 1997
3. Ingram VM: A specific chemical difference between the globins of normal human and sickle cell anemia haemoglobin. Nature 178:792, 1956
4. Brittenham GM, Schechter AN, Noguchi CT: Hemoglobin S polymerization. Primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood 65:183, 1985
5. Wood WG, Bunch C, Kelly S, Gunn Y, Breckon G: Control of haemoglobin switching by a developmental clock. Nature 313:320, 1985
6. Stamatoyannopoulos JA, Nienhuis AW: Therapeutic approaches to hemoglobin switching in treatment of the hemoglobinopathies. Annu Rev Med 43:487, 1992
7. Nagel RL, Bookchin RM: Structural bases of the inhibitory effects of Hb F and A2 on the polymerization of Hb S. Proc Natl Acad Sci USA 76:670, 1979
8. Perrine RP: Benign sickle cell anemia. Lancet 2:1163, 1972
9. Brittenham G, Lozoff B, Harris JW, Sharma VS, Narasimhan S: Sickle cell anemia and trait in a population in southern India. Am J Hematol 2:25, 1977
10. Wood WG, Pembrey ME, Serjeant GR, Perrine RP, Weatherall DJ: Hb F synthesis in sickle cell anaemia: A comparison of Saudi Arab cases with those of African origin. Br J Haematol 45:431, 1980
11. Perrine RP: Natural history of sickle cell anemia in Saudi Arabs. Ann Intern Med 88:1, 1978
12. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN: Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 318:96, 1988
13. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease: Life expectancy and risk factors for early death. N Engl J Med 330:1639, 1994
14. DeSimone J, Heller P, Hall L, Zwiers D: 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 79:4428, 1982
15. + thalassemia. N Engl J Med 307:1469, 1982
16. Ley TJ, DeSimone J, Noguchi CT: 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62:370, 1983
17. McDonagh KT, Dover GJ, Donahue RE, Nathan DG: Hydroxyurea-induced Hb F production in anemic primates: Augmentation by erythropoietin, growth factors, and sodium butyrate. Exp Hematol 20:1156, 1992
18. Dover GJ, Humphries RK, Moore JG: Hydroxyurea induction of hemoglobin F production in sickle cell disease: Relationship between cytotoxicity and F-cell production. Blood 67:735, 1986
19. Charache S, Dover GJ, Moyer MA, Moore JW: Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69:109, 1987
20. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73, 1993
21. Nagel RL, Vichinsky E, Shah M: F-reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: A double blind study. Blood 81:9, 1993
22. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR: Multicenter study of hydroxyurea in sickle cell anemia: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317, 1995
23. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ, Multicenter Study of Hydroxyurea: Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 89:1078, 1997
24. Ohene-Frempong HK, Bulgarelli W, Schursky HM: Hydroxyurea increases Hb F production in children with sickle cell disease. Blood 82:3258, 1993
25. Ferster A, Vermylen C, Cornu G: Hydroxyurea for treatment of severe sickle cell anemia: A pediatric trial. Blood 88:1960, 1996
26. Schechter AN, Rodgers G: Hydroxyurea in sickle cell disease. N Engl J Med 334:333, 1996
27. Maier-Redelsperger M, deMontalembert M, Flahault A, Neonato MG, Ducrocq R, Masson M-P, Girot R, Elion J: Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 91:4472, 1998
28. Partington GA, Yarwood NJ, Rutherford TR: Human globin gene transcription in injected Xenopus oocytes: Enhancement by sodium butyrate. EMBO J 3:2787, 1984
29. Perrine SP, Rudolph A, Faller DV: Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA 85:8540, 1988
30. Perrine SP, Miller BA, Faller DV, Cohen RA, Vichinsky EP, Hurst D, Lubin BH, Papayannopoulou T: Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and β thalassemia. Blood 74:454, 1989
31. Constantoulakis P, Knitter G, Stamatoyannopoulous G: On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-azaC and araC. Blood 74:1963, 1989
32. Blau A, Constantoulakis P, Shaw CM, Stamatoyannopoulos G: Fetal hemoglobin induction with butyric acid: Efficacy and toxicity. Blood 81:529, 1993
33. Safaya S, Ibrahim A, Reider RF: Augmentation of γ globin gene promoter activity by carboxylic acids and components of the human β-globin locus control region. Blood 84:3929, 1994
34. Liakopoulou E, Blau C, Li Q: Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 86:3227, 1995
35. Perrine SP, Dover GH, Daftari P, Walsh CT, Jin YX, Mays A, Faller DV: Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. Br J Haematol 88:555, 1994
36. Burns LJ, Glauber JG, Ginder GD: Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. Blood 72:1536, 1988
37. Ginder GD, Whitters MJ, Pohlman JK: Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc Natl Acad Sci USA 81:3954, 1984
38. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 328:81, 1993
39. Sher GD, Entsuah B, Ginder G, Dover G, Berkovitch M, Lewis N, Perrine S, Olivieri NF: Intravenous arginine butyrate increases γ-globin mRNA, F-reticulocytes and hemoglobin F in patients with sickle cell disease. 19th Annual Meeting of the National Sickle Cell Disease Program. 1994, p 177
40. Dover GJ, Brusilow S, Charache S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84:339, 1994
41. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ: Oral sodium phenylbutyrate therapy in homozygous β thalassemia: A clinical trial. Blood 85:43, 1995
42. Wintersberger E, Mudrak I, Wintersberger U: Butyrate inhibits mouse fibroblasts at a control point in the G1 phase. J Cell Biochem 21:239, 1983
43. Toscani A, Soprano DR, Soprano KJ: Molecular analysis of sodium butyrate induced growth arrest. Oncogene Res 3:223, 1988
44. Charollais RH, Buguet C, Mester J: Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31. J Cell Physiol 145:46, 1990
45. Fibach E, Prosmanne J, Rodgers GP, Samid D: Enhanced fetal hemoglobin production by phenylacetate and 4 phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia. Blood 82:2203, 1993
46. Vaziri C, Stice LL, Faller DV: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma-mediated signals. Cell Growth Differ 9:465, 1998
47. Faller DV, Perrine SP: Butyrate in the treatment of sickle cell disease and β thalassemia. Curr Opin Hematol 2:109, 1995
48. Stamatoyannopoulos G, Blau CA, Nakamoto B, Josephson B, Li Q, Liakopoulou E, Pace B, Papayannopoulou T, Brusilow SW, Dover G: Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 84:3198, 1994
49. Charache S, Barton FB, Moore RD: Hydroxyurea and sickle cell anemia: Clinical utility of a myelosuppressive "switching" agent: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 75:300, 1996
50. Orringer EP, Blythe DS, Johnson AE, Phillips GJ, Dover GJ, Parker JC: Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 78:212, 1991
51. Ballas SK, Dover GJ, Charache S: Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 32:104, 1989
52. Perrine SP, Greene MF, Faller DV: Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 312:334, 1985
53. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS: Induction of γ-globin by histone deacetylase inhibitors. Blood 90:2075, 1997
54. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387:43, 1997
55. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transciptional repression. Cell 89:349, 1997
56. Torkelson S, White GL, Phipps K: Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids. Blood Cells Mol Dis 20:150, 1996
57. Boosalis MS, Ikuta T, Pace BS: Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids. Blood Cells Mol Dis 23:434, 1997